These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25935860)

  • 1. Emerging therapies in bone metastasis.
    Clément-Demange L; Clézardin P
    Curr Opin Pharmacol; 2015 Jun; 22():79-86. PubMed ID: 25935860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.
    Hiraga T
    Expert Opin Investig Drugs; 2016; 25(3):319-34. PubMed ID: 26778342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for the treatment of bone metastasis.
    Pantano F; Iuliani M; Zoccoli A; Fioramonti M; De Lisi D; Fioroni I; Ribelli G; Santoni M; Vincenzi B; Tonini G; Santini D
    Expert Opin Emerg Drugs; 2015; 20(4):637-51. PubMed ID: 26113304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future treatment of bone metastases.
    Lipton A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6305s-6308s. PubMed ID: 17062719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular basis of bone metastasis formation and its targeted therapy].
    Tímár J
    Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets for bone metastases in breast cancer.
    Clézardin P
    Breast Cancer Res; 2011 Apr; 13(2):207. PubMed ID: 21586099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A; Balakumaran A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone metastasis: mechanisms, therapies, and biomarkers.
    Clézardin P; Coleman R; Puppo M; Ottewell P; Bonnelye E; Paycha F; Confavreux CB; Holen I
    Physiol Rev; 2021 Jul; 101(3):797-855. PubMed ID: 33356915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
    Yoneda T
    Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic and clinical associations between bone and cancer.
    He F; Matsumoto Y
    Immunol Med; 2020 Sep; 43(3):103-106. PubMed ID: 32301686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in bone-targeted therapies of metastatic prostate cancer.
    Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
    Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone-Targeted Therapies in Cancer-Induced Bone Disease.
    Sousa S; Clézardin P
    Calcif Tissue Int; 2018 Feb; 102(2):227-250. PubMed ID: 29079995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer].
    Taguchi T
    Clin Calcium; 2011 Mar; 21(3):429-38. PubMed ID: 21358065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The osteoclast, bone remodelling and treatment of metabolic bone disease.
    Boyce BF; Rosenberg E; de Papp AE; Duong LT
    Eur J Clin Invest; 2012 Dec; 42(12):1332-41. PubMed ID: 22998735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
    Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic modeling of bone metastasis, microenvironment and therapy: Integrating parathyroid hormone (PTH) effect, anti-resorptive and anti-cancer therapy.
    Coelho RM; Lemos JM; Alho I; Valério D; Ferreira AR; Costa L; Vinga S
    J Theor Biol; 2016 Feb; 391():1-12. PubMed ID: 26657065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
    Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
    J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma.
    Terpos E; Confavreux CB; Clézardin P
    Bonekey Rep; 2015; 4():744. PubMed ID: 26512321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.